| Domain | POLE-specific conclusion | Strongest quantitative/contextual evidence | Evidence type and applicability | Key source with date/DOI or NCT |
|---|---|---|---|---|
| Definition / classification | Photosensitive occipital lobe epilepsy (POLE; also reported historically as idiopathic photosensitive occipital lobe epilepsy) is best treated as a rare reflex focal epilepsy phenotype at the intersection of photosensitive epilepsy and occipital epilepsy, not as synonymous with all photosensitive epilepsies. | Search history identified syndrome-specific publications from 1995, 2014, 2015, 2023, but accessible evidence in this session was largely broader photosensitivity literature; therefore syndrome boundaries are real but direct quantitative extraction here is limited. | Mixed: indirect/contextual; high face validity but limited direct extractable POLE data in-session. | POLE-specific papers identified in search history: Guerrini et al., 1995, DOI: 10.1111/j.1528-1157.1995.tb01631.x; Politi-Elishkevich et al., 2014, DOI: 10.1177/0883073812473366; Koutroumanidis et al., 2015, DOI: 10.1684/epd.2015.0765; Cerrahoğlu Şirin et al., 2023, DOI: 10.1002/epd2.20011 (pqac-00000000) |
| Identifiers / ontology | No dedicated POLE MONDO identifier was established from retrieved evidence; MONDO does contain photosensitive epilepsy. A disease-knowledge entry should therefore map POLE provisionally beneath focal reflex/photosensitive epilepsy concepts until a dedicated ontology term is confirmed. | Open Targets returned MONDO_0015643 for “photosensitive epilepsy,” with no disease-target associations and no POLE-specific target record retrieved. | Direct database-context for broader photosensitive epilepsy; only partial applicability to POLE. | Open Targets context for MONDO:0015643 “photosensitive epilepsy” (pqac-00000000) |
| Genetics | No single causal gene is established for POLE specifically from retrieved evidence. Genetic conclusions should not be overgeneralized from broader photosensitive epilepsy cohorts. | In a 35-patient cohort with genetic photosensitivity, pathogenic variants involved SCN1A (7), CHD2 (6), TPP1 (3), SYNGAP1 (3), GABRA1 (2), plus single cases in GABRG2, KCTD7, MFSD8, KCNC1, GBA, CACNA1A, KCNMA1, FLNA, SZT2, SLC2A1, one 5q33.2-34 deletion, and 3 mitochondrial variants; ion-channel genes accounted for 46.7%; 77.7% remained photosensitive at 1 year. | Direct human cohort for genetic photosensitivity; extrapolation to POLE only, because the cohort was heterogeneous and not occipital-lobe-specific. | Niu et al., 2022, Front Neurol, DOI: 10.3389/fneur.2022.907228 (pqac-00000001, pqac-00000002, pqac-00000003, pqac-00000004) |
| EEG / diagnosis | POLE diagnosis should rely on electroclinical correlation: visually triggered focal occipital seizures and/or occipital-dominant photoparoxysmal/photoconvulsive responses, with careful distinction from generalized photosensitivity syndromes. | Broader PSE literature shows IPS is most sensitive around 15–20 flashes/s; ~49% may also react at 50 flashes/s; standardized IPS can detect epileptiform discharges in 85% of susceptible patients in one cited series; PPR may begin in occipital cortex and spread to parietal/central regions at higher frequencies. | Human EEG/IPS evidence; strong for photosensitivity evaluation, moderate extrapolation to POLE diagnostic workflow. | da Silva & Leal, 2017, Seizure, DOI: 10.1016/j.seizure.2017.04.001 (pqac-00000006, pqac-00000007, pqac-00000011, pqac-00000013); Covanis et al., 2004, Epilepsia, DOI: 10.1111/j.0013-9580.2004.451006.x (pqac-00000008) |
| Epidemiology | True POLE prevalence/incidence remains unclear from retrieved evidence; it appears under-recognized and much rarer than generic photosensitive epilepsy. | Broader PSE occurs in ~1 in 4,000 population, incidence ~1.1/100,000/year, ~5-fold higher at ages 7–19, with female excess; PPR prevalence in epilepsy clinic populations cited at 5.6%, and 7.3% in ages 10–20 years. | Broader epidemiologic extrapolation only; not POLE-specific. | da Silva & Leal, 2017, DOI: 10.1016/j.seizure.2017.04.001 (pqac-00000007, pqac-00000010, pqac-00000013) |
| Triggers / environmental factors | POLE is expected to share the core visual-trigger architecture of photosensitive epilepsies: flicker, pattern, luminance contrast, and specific color combinations. | Triggering frequencies are typically 8–50 Hz with maximum sensitivity around 20 Hz; long-wavelength red light and red-blue alternation are especially provocative, blue-green less so; reported real-world triggers include television, video games, flashlights, discotheques, venetian blinds, escalators, and patterned materials; sleep deprivation, alcohol, and stress lower threshold. | Human observational/review evidence; strong for trigger counseling, indirect for POLE. | Covanis et al., 2004, DOI: 10.1111/j.0013-9580.2004.451006.x (pqac-00000008, pqac-00000009); da Silva & Leal, 2017, DOI: 10.1016/j.seizure.2017.04.001 (pqac-00000006, pqac-00000011, pqac-00000013) |
| Treatment | No POLE-specific randomized treatment data were retrieved. In practice, management is likely to combine trigger reduction with standard antiseizure therapy selected for seizure type and syndrome context. | In broader visual-sensitive epilepsy, valproate was reported as first-line, with 85% seizure freedom in one visually sensitive series and 81% seizure freedom in 67 IPS-sensitive patients; benzodiazepines and ethosuximide also reported effective. Colored lenses suppressed PPR in 77% and reduced it in 19% in one review summary. | Human clinical review evidence for broader photosensitivity; extrapolation to POLE, especially if focal semiology predominates. | Covanis et al., 2004, DOI: 10.1111/j.0013-9580.2004.451006.x (pqac-00000009); da Silva & Leal, 2017, DOI: 10.1016/j.seizure.2017.04.001 (pqac-00000006) |
| Prognosis | POLE prognosis is insufficiently quantified from retrieved direct evidence; available literature suggests many photosensitive epilepsies are time-limited, but this cannot be assumed uniformly for POLE. | Broader PSE data suggest remission in the second decade in about two-thirds of valproate-treated patients and over 50% of untreated patients; 80% of pattern-sensitive epilepsy patients were seizure-free for >2 years in one cited series. In the genetic photosensitivity cohort, 77.7% still showed photosensitivity at 1 year. | Mixed: broader syndrome extrapolation plus heterogeneous genetic cohort; low-to-moderate direct applicability to POLE. | da Silva & Leal, 2017, DOI: 10.1016/j.seizure.2017.04.001 (pqac-00000007, pqac-00000013); Niu et al., 2022, DOI: 10.3389/fneur.2022.907228 (pqac-00000003, pqac-00000004) |
| Trials / real-world implementation | Clinical trials in this space largely use the human photosensitivity model (suppression of PPR/SPR during IPS) rather than POLE-specific seizure outcomes. | Completed/terminated trials include brivaracetam (NCT00401648, n=20), JNJ-26489112 (NCT00579384, n=12), BGG492/AMPA antagonist (NCT00784212, n=13), ICA-105665 (NCT00979004, terminated after SAE; n=13), ACT-709478 (NCT03239691, n=5), E2730 (NCT03603639, n=6), specialty lenses (NCT04076410, n=28), RLS103 (NCT05678881, n=2), NPT 2042 (NCT06525649, n=5). Endpoints are EEG biomarker suppression, not POLE natural-history endpoints. | Direct interventional evidence for photosensitivity-platform pharmacodynamics; indirect for POLE treatment efficacy. | ClinicalTrials.gov records: NCT00401648, NCT00579384, NCT00784212, NCT00979004, NCT03239691, NCT03603639, NCT04076410, NCT05678881, NCT06525649 (pqac-00000022, pqac-00000023, pqac-00000024, pqac-00000025, pqac-00000026, pqac-00000027, pqac-00000028, pqac-00000029) |
| Animal model / comparative biology | No POLE-specific animal model was retrieved. The strongest natural model is the photosensitive baboon, but it models genetic generalized photosensitive epilepsy rather than focal occipital POLE. | In Papio hamadryas papio, generalized spike-wave discharges occurred in 49% of 671 baboons at 4–6 Hz; photoepileptic responses in 23% of epileptic baboons, maximal at 20–25 Hz IPS; heritability estimates included h2=0.33 for spontaneous seizures and h2=0.19 for IEDs; RBFOX1 emerged as a candidate association. Imaging and intracranial EEG implicate widespread visual, parietal, frontal, motor, and thalamic networks. | Direct natural-disease/model evidence for photosensitive GGE; only mechanistic extrapolation to POLE. | Szabo & Salinas, 2021, DOI: 10.1016/j.yebeh.2021.108012 (pqac-00000016, pqac-00000018); Szabo & Salinas, 2022, DOI: 10.3389/fvets.2022.908801 (pqac-00000015); Szabó et al., 2012, DOI: 10.1016/j.eplepsyres.2012.02.016 (pqac-00000014, pqac-00000017) |
| Major evidence gaps | The main limitation is lack of accessible POLE-specific primary data in this session for identifiers, prevalence, inheritance, variant spectrum, standardized diagnostic criteria, prognosis, and therapy response. | No retrieved POLE-specific omics, epigenetic studies, infectious causes, validated biomarkers, WES/WGS utility studies, surgery series, gene/cell/RNA therapy, or dedicated animal model. Open Targets showed no disease-target associations for MONDO photosensitive epilepsy. | Direct evidence-gap conclusion. This should be made explicit in the final report to avoid overclaiming from broader PSE literature. | Open Targets context plus retrieved literature/trials landscape (pqac-00000000, pqac-00000022, pqac-00000023, pqac-00000024, pqac-00000025, pqac-00000026, pqac-00000027, pqac-00000028, pqac-00000029) |


*Table: This table calibrates what can be concluded specifically for photosensitive occipital lobe epilepsy versus what must be extrapolated from broader photosensitive epilepsy research. It is useful for structuring a cautious, evidence-graded disease report without overstating gene, epidemiology, or treatment claims.*